Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone952-426-6140
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Vision Sciences (NASDAQ:CGNT) Frequently Asked Questions
What is Vision Sciences' stock symbol?
Vision Sciences trades on the NASDAQ under the ticker symbol "CGNT."
How were Vision Sciences' earnings last quarter?
Vision Sciences Inc. (NASDAQ:CGNT) released its earnings results on Tuesday, November, 3rd. The medical device company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.01. The medical device company had revenue of $11.80 million for the quarter, compared to the consensus estimate of $11.45 million. View Vision Sciences' Earnings History.
What price target have analysts set for CGNT?
1 analysts have issued 12-month price objectives for Vision Sciences' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Vision Sciences' stock price to reach $4.00 in the next twelve months. View Analyst Price Targets for Vision Sciences.
What is the consensus analysts' recommendation for Vision Sciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vision Sciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vision Sciences.
Has Vision Sciences been receiving favorable news coverage?
Media coverage about CGNT stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vision Sciences earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an impact on the stock's share price in the near term.
Who are some of Vision Sciences' key competitors?
Some companies that are related to Vision Sciences include Medtronic (MDT), SONOVA HLDG AG/ADR (SONVY), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), Natus Medical (BABY), AxoGen (AXGN), Viewray (VRAY), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR) and Cutera (CUTR).
What other stocks do shareholders of Vision Sciences own?
Who are Vision Sciences' key executives?
Vision Sciences' management team includes the folowing people:
- Mr. Darin Hammers, Pres, CEO & Director (Age 53)
- Mr. Brett A. Reynolds, Sr. VP, CFO & Corp. Sec. (Age 49)
- Mr. Chris Arnold, VP of Global Sales (Age 50)
- Mr. Larry Heinemann, VP of Corp. Devel. (Age 66)
- Mr. Ash Keswani, Sr. VP of Marketing & Bus. Devel.
How do I buy shares of Vision Sciences?
Shares of CGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vision Sciences' official website?
How can I contact Vision Sciences?
Vision Sciences' mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The medical device company can be reached via phone at 952-426-6140 or via email at [email protected]
MarketBeat Community Rating for Vision Sciences (NASDAQ CGNT)
MarketBeat's community ratings are surveys of what our community members think about Vision Sciences and other stocks. Vote "Outperform" if you believe CGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
